Thread: Osta-Rx What can I expect?

You would be looking at solid lean gains. Great product for bridging also.

That only took 12 days

Originally Posted by Silver_Back

That only took 12 days

Be patient my brother. I'm going to start monitoring this section better.

Will be available mid March.

Originally Posted by Silver_Back

That only took 12 days

LOL, oh, Saney

Originally Posted by Silver_Back

If I were to use this future supplement by IronMagLabs, would could I expect from using this product in a stand-alone cycle?

Whats the compound(s)?

20mg placebo compound, 20mg horse semen. gich.

Originally Posted by Silver_Back

That only took 12 days

IronMagLabs Bodybuilding Supplements & Prohormones: Osta Rx

Interesting

Google Ostarine.

This looks like the second coming of Christ on sliced bread with a cookie brought to you by a 27-year-old Kim Basinger.

it's a SARM (Selective Androgen Receptor Modulator)

in correct doses, it can be as great as a steroid minus the hormone (no PCT, and female friendly)

Expect high dose anavar or winny like results without the sides.

Originally Posted by heavyiron

Expect high dose anavar or winny like results without the sides.

IN4 a bulk order

Yes the product is going to be amazing! I'm excited about the reviews and know guys are waiting for it to come in!!!

I notice its got a short half life of 24 hrs. What do think the detection time as far as testing is, 2 weeks?

would it be ok to run Ostarine in PCT for a METHA-DROL EXTREME cycle ?

cant wait for osta to come out

Originally Posted by 0612Legend

I notice its got a short half life of 24 hrs. What do think the detection time as far as testing is, 2 weeks?

Within two weeks imo would be detectable. However this depends entirely on your body make up as everyone vary here.

Originally Posted by dworld

would it be ok to run Ostarine in PCT for a METHA-DROL EXTREME cycle ?

Absolutely as it is a SARM.

Originally Posted by jwa

cant wait for osta to come out

It's going to be a hot item for sure!!!

can I run it in PCT from a Halo Ext only 6 week cycle? (I figure for sure, but it doesn't hurt to ask right)
Thanks

Originally Posted by fatsopower

can I run it in PCT from a Halo Ext only 6 week cycle? (I figure for sure, but it doesn't hurt to ask right)
Thanks

Absolutely

If a guy was to use ostarx while using aas would there be issues with binding and such? Better to wait for pct?

Originally Posted by Little Guy

If a guy was to use ostarx while using aas would there be issues with binding and such? Better to wait for pct?

I don't see a problem with it, just becasue it's intended use is PCT or bridging, dosent mean is can't be properly stacked in a given cycle.

Any idea on relative binding affinity?

Hopefully Heavy will come in here to answer this one.

Patrick arnold thinks that ostarine is suppresive. therefore imo why would anyone use it during pct?

Why is IML saying it can be used for pct and bridging?

GTx Announces That Ostarine Achieved Primary Endpoint Of Lean Body Mass And A Secondary Endpoint Of Improved Functional Performance

GTx, Inc.
09 Dec 2006


GTX, the Men's Health Biotech Company, today announced that ostarine, a first-in-class selective androgen receptor modulator (SARM), met its primary endpoint in a Phase II proof of concept double blind, randomized, placebo controlled clinical trial in 120 subjects (60 elderly men and 60 postmenopausal women).

Without a prescribed diet or exercise regimen, all subjects treated with ostarine had a dose dependent increase in total lean body mass (muscle), with the 3 mg cohort achieving an increase of 1.3 kg compared to baseline and 1.4 kg compared to placebo (p<0.001) after three months of treatment.

Treatment with ostarine also resulted in a dose dependent improvement in functional performance measured by a stair climb test, with the 3 mg cohort achieving a clinically significant improvement in both speed (p=0.006) and power (p=0.005).

Ostarine continued to demonstrate a favorable safety profile, with no serious adverse events reported. Ostarine also exhibited tissue selectivity with beneficial effects on lean body mass and performance and with no apparent change in measurements for serum PSA (prostate), sebum production (skin and hair), or serum LH (pituitary) compared to placebo.

The Phase II clinical trial evaluated four doses of ostarine (0.1 mg, 0.3 mg, 1 mg, and 3 mg) versus placebo for three months in 60 elderly men (average age 66 years) and 60 postmenopausal women (average age 63 years). The trial was conducted in five clinical sites in the United Kingdom and Germany.

A summary of the topline data is as follows:

-- Among females (n=56), ostarine treatment resulted in a dose dependent increase in LBM with the 3 mg dose having an increase of 1.7 kg compared to baseline and an increase of 1.4 kg compared to placebo (p=0.02).

-- Among males (n=58), treatment with a 1 mg dose of ostarine resulted in a LBM increase of 0.7 kg compared to baseline and an increase of 1.2 kg compared to placebo (p=0.03), and treatment with a 3 mg dose of ostarine resulted in an increase of 1.0 kg compared to baseline and an increase of 1.4 kg compared to placebo (p=0.005).

-- Total tissue percent fat decreased compared to placebo in a dose dependent fashion and achieved statistical significance at the 1 mg dose (p=0.02) and 3 mg dose (p=0.006) of ostarine.

Total fat mass was lower in subjects receiving either the 3 mg or 1 mg ostarine dose, although not at a statistically significant level (p = 0.08 for both doses). For subjects receiving the 3 mg ostarine dose, total fat on average declined 0.6 kg compared to placebo.

The site of fat loss differed among male and female subjects, with males losing fat primarily from the trunk and abdomen, and females losing fat primarily from the thighs and legs.

-- In this short trial, ostarine had no apparent effect on bone mineral density, and bone turnover markers results were mixed. In preclinical in vitro and in vivo models, ostarine demonstrated both anabolic and antiresorptive activity on bone. A longer clinical study is necessary to demonstrate the actual effects of ostarine on bone.

-- Ostarine continued to demonstrate a favorable safety profile, with no serious adverse events reported.

-- At the end of three months, no subject had clinically meaningful levels in liver enzyme tests. However, one female discontinued the study per protocol due to elevated liver enzymes which returned to baseline.

-- Ostarine treatment resulted in a dose dependent decrease in both LDL and HDL cholesterol levels, with the average LDL/HDL ratio for all doses tested remaining in the low cardiovascular risk category.

-- Ostarine treatment resulted in no apparent effect on serum PSA (prostate), sebum production (skin and hair), or serum LH (pituitary).